Detail
| LncRNA Name | CTA |
| Synonyms | NA, CERNA3 |
| Region | GRCh38_8:56074592-56075274 Sequence |
| Ensembl | ENSG00000253603 |
| RefSeq | NR_149110 |
| Circulating | ✘ |
| Drug-resisitant | ✔ |
| Prognostic | ✘ |
| MiRNA | ✔ |
| Variant | ✘ |
| TF | ✘ |
| Methylation | ✘ |
| Cancer Name | osteosarcoma |
| ICD-0-3 | M9180/3 |
| Methods | qPCR, Western blot, MIT, Luciferase reporter assays |
| Sample | osteosarcoma tissues, cell lines (Saos-2, U-2OS and MG-63) |
| Expression Pattern | down-regulated |
| Function Description | Our data showed that lncRNA CTA was markedly downregulated in OS tissues compared to their matched non-tumor tissues. In addition, OS patients with low lncRNA CTA levels showed a worse prognosis when compared with those with high expression of lncRNA CTA. LncRNA CTA could be activated by doxorubicin (DOX), and could promote OS cell apoptosis by competitively binding miR-210, while inhibit cell autophagy. |
| Pubmed ID | 28415557 |
| Year | 2017 |
| Title | Long non-coding RNA CTA sensitizes osteosarcoma cells to doxorubicin through inhibition of autophagy |
| External Links |
| Links for CTA | GenBank HGNC lncrnadb Noncode |
| Links for osteosarcoma | Omim Cosmic |
CopyRight © College of Bioinformatics Science and Technology, Harbin Medical University, China.